SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tim Davies who wrote (21288)4/23/1999 8:11:00 PM
From: Mkilloran  Read Replies (1) of 23519
 
Tim...Alibra is the next generation ED product that Vivus has in Phase III FDA trials now.

It's expected to be completed with the trials by Sept 99 and then submitted to the FDA for final review.

Should be onsale by 2nd qtr yr 2000.

The comparison of Alibra to Muse :
Alibra can be stored at room temp, Muse can not.
Alibra is more efficent that Muse.
Alibra is a blend of two drugs.
Alibra has less side effects than Muse.
Alibra cost less to produce than MUSE.
Alibra is smaller than MUSE.
Alibra comes in one single dose size, Muse has three dose sizes.
Expect sales of Alibra to exceed those of Muse worldwide as it is fully launched.

Expect the launch of Alibra to be much faster than MUSE.
Expect current partners to pay additional milestone payments for the rights to sell Alibra.

Expect Vivus to have both products available for sale in yr 2000 and beyond.

NEW and improved better than MUSE.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News